20 December 2006
W. L. Gore & Associates announced today the first use of the GORE Embolic Liquid (GEL) at Oregon Health & Science University (OHSU) by Stanley Barnwell, M.D., Ph.D. Dr. Barnwell and his team successfully treated the first patient in the MAGELAN trial (prospective, Multicenter, feAsibility trial to evaluate the safety and performance of Gore Embolic Liquid used in presurgical embolization of cerebral Arteriovenous malformatioN).
29 November 2006
W. L. Gore & Associates today announced that Georgetown University Medical Center in Washington, D.C. was the site of the first U.S. implant of the GORE PROPATEN Vascular Graft since its FDA clearance earlier this month.
16 November 2006
Gore transcends mechanical solutions for lower-limb surgery with a ePTFE-heparin combination
03 November 2006
W. L. Gore & Associates, Inc. announced that it will no longer sell or market products in the plastic surgery market.
27 July 2006
W. L. Gore & Associates announced today that site initiation and enrollment has begun in the EMPiRE (Embolic Protection with flow Reversal) Clinical Study. This investigational clinical study is designed to demonstrate the safety and efficacy of the GORE Neuro Protection System when used for embolic protection during carotid artery stenting procedures.
07 July 2006
W. L. Gore & Associates, Inc. (Gore) announced today that it has acquired Neural Intervention Technologies, Inc. (NIT), a medical device company developing a novel liquid embolic material for the treatment of blood vessel defects.
26 June 2006
W.L. Gore & Associates offers GORE DUALMESH® PLUS Biomaterial, which has recently been reported to inhibit MRSA adherence in laboratory testing.
07 April 2006
W. L. Gore & Associates, Inc. (Gore) has introduced GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement configured for open surgical staplers.
09 January 2006
W. L. Gore & Associates, Inc., maker of GORE-TEX® fabric and thousands of other innovative products, today announced it has earned a position on FORTUNE's annual list of the "100 Best Companies to Work For" for the 9th consecutive year.
17 October 2005
First Patient Treated in VIBRANT Study of GORE VIABAHN® Endoprosthesis vs. Bare Nitinol Stent to Treat Lower Limb Vascular Disease.
05 October 2005
W. L. Gore & Associates, Inc. (Gore) announced today that it has acquired Carmeda AB, a Sweden-based manufacturer of the most clinically proven, hemocompatible surface coating for medical devices.
07 September 2005
The Society of Chemical Industry (America Section) has named Robert W. Gore, Ph.D., Chairman of W. L. Gore & Associates, the winner of the 2005 Perkin Medal.
24 August 2005
The September 2005 issue of Fast Company magazine turns the spotlight on Terri Kelly, the president and CEO of W. L. Gore & Associates.
14 June 2005
Gore & Associates has received US Food and Drug Administration (FDA) approval to market the GORE VIABAHN® Endoprosthesis (6, 7, and 8 mm diameters) for use in the Superficial Femoral Artery (SFA).
11 May 2005
Between May 12 and 15, cardiac surgeons from all over the country will in Phoenix to learn about new and emerging therapies in cardiac surgery.
28 March 2005
W. L. Gore & Asssociates, Inc., announced today an agreement with Datascope Corp. to exclusively distribute the entire InterVascular portfolio of polyester products available for sale in the United States.
24 March 2005
W. L. Gore & Associates, Inc. (Gore), has received Food and Drug Administration (FDA) approval to market the GORE TAG Thoracic Endoprosthesis.
11 January 2005
W. L. Gore & Associates, Inc., maker of GORE-TEX® fabric and thousands of other innovative products, today announced it has earned a position on Fortune’s annual list of the U.S. "100 Best Companies to Work For" for the 8th consecutive year.
08 December 2004
W. L. Gore & Associates, Inc. has received U.S. Food and Drug Administration (FDA) approval to market the GORE VIATORR® Endoprosthesis, an advanced technology, implantable device to treat portal hypertension in both de novo and revision Transjugular Intrahepatic Portosystemic Shunt (TIPS) procedures.
24 December 2004
When Fast Company magazine was looking for innovation, it went straight to W. L. Gore & Associates.
18 November 2004
W. L. Gore & Associates, Inc. (Gore), today announced that it has acquired substantially all of the assets of ArteriA Medical Science Inc. (ArteriA), a privately held San Francisco-based company and the manufacturer of the Parodi Anti-Emboli System* (PAES and PAES II) and other related devices.
10 May 2004
W. L. Gore & Associates, Inc. (Gore), the leading manufacturer of expanded polytetrafluoroethylene (ePTFE) peripheral vascular grafts announced today the addition of collagen-coated polyester vascular prostheses and vascular patches to its medical products offering.
25 March 2004
Frost & Sullivan recognized W. L. Gore & Associates’ Medical Products Division with the 2004 Endovascular Product Leadership of the Year for its GORE EXCLUDER® Bifurcated Endoprosthesis.
05 January 2004
W. L. Gore & Associates, Inc., today announced it has again been selected as one of Fortune's "100 Best Companies to Work For." Gore is ranked 12th in the magazine’s January 12, 2004, feature story.
25 September 2003
The Society of Laparoendoscopic Surgeons (SLS) recognized the GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement Material as one of the “Innovations of the Year”.
17 September 2003
W. L. Gore & Associates, Inc., today announced it is selling its GLIDE® dental floss brand to Procter & Gamble of Cincinnati, Ohio.
20 June 2003
W. L. Gore & Associates, Inc.,has introduced the GORE SEAMGUARD® Bioabsorbable Staple Line Reinforcement Material, an innovative, bioabsorbable membrane designed for reinforcing surgical staple lines in pulmonary and bariatric surgery.
01 June 2003
W. L. Gore & Associates, Inc., announces the introduction of the GORE RESOLUT ADAPT LT (Long-Term) Regenerative Membrane, an innovative, bioabsorbable membrane designed for improved healing of periodontal and bone defects.
06 May 2003
W. L. Gore & Associates, Inc., announces the assumption of responsibilities from Nobel Biocare for worldwide distribution and sales of the Gore Regenerative Products beginning June 1, 2003.
24 April 2003
W. L. Gore & Associates, Inc. has announced that the GORE-TEX® INTERING Vascular Graft is now available in 4-6, 4-7 and 6 mm sizes specifically configured for vascular access.
19 March 2003
W. L. Gore & Associates, Inc., has received 510(k) clearance from the U.S. Food and Drug Administration to market the VIABIL Biliary Endoprosthesis.
18 March 2003
W. L. Gore & Associates, Inc., has received 510(k) clearance from the U.S. Food and Drug Administration to market the VIATORR Endoprosthesis.
06 November 2002
W. L. Gore & Associates, Inc. received FDA approval to market the EXCLUDER Bifurcated Endoprosthesis in the United States.
09 September 2002
W. L. Gore & Associates, Inc., (Gore) has taken another step toward U.S. approval of the EXCLUDER Bifurcated Endoprosthesis following a positive recommendation of their Pre-Market Approval Application from the Circulatory System Devices Panel advising the U.S. Food and Drug Administration’s Center for Devices and Radiological Health.
21 May 2002
The latest vascular graft offering from W.L. Gore & Associates, a leader in vascular surgical products for more than two decades, GORE-TEX® INTERING Vascular Graft redefines graft performance by reducing kinking and compression.
5 March 2002
W. L. Gore & Associates, Inc., has received 510(k) clearance from the U.S. Food and Drug Administration to market the VIABAHN Endoprosthesis.